HK1161125A1 - Galenic formulations comprising aliskiren - Google Patents

Galenic formulations comprising aliskiren

Info

Publication number
HK1161125A1
HK1161125A1 HK12101945.0A HK12101945A HK1161125A1 HK 1161125 A1 HK1161125 A1 HK 1161125A1 HK 12101945 A HK12101945 A HK 12101945A HK 1161125 A1 HK1161125 A1 HK 1161125A1
Authority
HK
Hong Kong
Prior art keywords
aliskiren
galenic formulations
galenic
formulations
Prior art date
Application number
HK12101945.0A
Other languages
English (en)
Chinese (zh)
Inventor
Sabine Desset-Brthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1161125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1161125A1 publication Critical patent/HK1161125A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12101945.0A 2009-01-28 2012-02-27 Galenic formulations comprising aliskiren HK1161125A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (en) 2009-01-28 2010-01-27 Galenic formulations of organic compounds

Publications (1)

Publication Number Publication Date
HK1161125A1 true HK1161125A1 (en) 2012-08-24

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101945.0A HK1161125A1 (en) 2009-01-28 2012-02-27 Galenic formulations comprising aliskiren

Country Status (28)

Country Link
US (1) US20110287100A1 (xx)
EP (1) EP2391345B1 (xx)
JP (1) JP2012516299A (xx)
KR (1) KR20110117199A (xx)
CN (1) CN102300558A (xx)
AR (1) AR075179A1 (xx)
AU (1) AU2010209787B2 (xx)
BR (1) BRPI1007452A2 (xx)
CA (1) CA2749531A1 (xx)
CL (1) CL2011001817A1 (xx)
CO (1) CO6400184A2 (xx)
EC (1) ECSP11011289A (xx)
ES (1) ES2525648T3 (xx)
HK (1) HK1161125A1 (xx)
IL (1) IL213918A0 (xx)
MA (1) MA33060B1 (xx)
MX (1) MX2011007779A (xx)
MY (1) MY153852A (xx)
NZ (1) NZ593622A (xx)
PE (1) PE20110943A1 (xx)
PL (1) PL2391345T3 (xx)
PT (1) PT2391345E (xx)
RU (1) RU2535090C2 (xx)
SG (1) SG172226A1 (xx)
TN (1) TN2011000307A1 (xx)
TW (1) TWI468191B (xx)
WO (1) WO2010086312A1 (xx)
ZA (1) ZA201104489B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
US20190054069A1 (en) * 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
US20210308054A1 (en) 2018-08-10 2021-10-07 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
GB2585411B (en) * 2019-02-22 2023-10-04 Catalent Uk Swindon Zydis Ltd Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
TW202045153A (zh) 2019-02-22 2020-12-16 英商康泰倫特英國斯文敦載迪斯有限公司 含伊布洛芬之醫藥組合物之塗層之黏聚最小化、通氣及保存
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
US20070224260A1 (en) * 2004-04-15 2007-09-27 Dr. Reddy's Laboratories Limited Dosage Form Having Polymorphic Stability
EP1799199B1 (en) * 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
CA2697437A1 (en) * 2007-09-28 2009-04-09 Novartis Ag Pharmaceutical combination of aliskiren and valsartan

Also Published As

Publication number Publication date
TWI468191B (zh) 2015-01-11
ZA201104489B (en) 2012-02-29
AR075179A1 (es) 2011-03-16
NZ593622A (en) 2013-12-20
CA2749531A1 (en) 2010-08-05
TN2011000307A1 (en) 2012-12-17
AU2010209787B2 (en) 2013-06-06
AU2010209787A1 (en) 2011-07-14
EP2391345A1 (en) 2011-12-07
MY153852A (en) 2015-03-31
WO2010086312A1 (en) 2010-08-05
MX2011007779A (es) 2011-08-12
CL2011001817A1 (es) 2012-01-13
PL2391345T3 (pl) 2015-03-31
CO6400184A2 (es) 2012-03-15
JP2012516299A (ja) 2012-07-19
US20110287100A1 (en) 2011-11-24
SG172226A1 (en) 2011-07-28
BRPI1007452A2 (pt) 2016-02-16
RU2011135417A (ru) 2013-03-10
KR20110117199A (ko) 2011-10-26
EP2391345B1 (en) 2014-09-03
MA33060B1 (fr) 2012-02-01
RU2535090C2 (ru) 2014-12-10
ES2525648T3 (es) 2014-12-26
IL213918A0 (en) 2011-07-31
ECSP11011289A (es) 2011-09-30
CN102300558A (zh) 2011-12-28
TW201038300A (en) 2010-11-01
PE20110943A1 (es) 2012-01-22
PT2391345E (pt) 2014-12-03

Similar Documents

Publication Publication Date Title
ZA201106050B (en) Dye-polymers formulations
PT3061445T (pt) Formulações farmacêuticas altamente concentradas
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
EP2504034A4 (en) TOPICAL IBUPROFEN FORMULATIONS
GB0815435D0 (en) Formulations
IL269369A (en) The vehicles are improved
GB2459691B (en) Formulations
IL218231A0 (en) Vesicular formulations
GB0823269D0 (en) Formulations
GB0919210D0 (en) Formulations
GB0821789D0 (en) Formulations
HK1161125A1 (en) Galenic formulations comprising aliskiren
ZA201106842B (en) Sanitizer formulations
EP2307021A4 (en) FORMULATIONS
IL217390A0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0917744D0 (en) Formulations
GB0914489D0 (en) Improved formulations
GB0918285D0 (en) Topical formulations
GB0918286D0 (en) Topical formulations
GB0807906D0 (en) Formulations
GB0811447D0 (en) Formulations
GB0816876D0 (en) Formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180127